3P BIOPHARMACEUTICALS SL - Spain 

Ranking results:

Past rankings:

2012
Criterium:Position:
Overall Score:> 1000
Networking Rank (Reputation):> 1000
Networking Rank (Reputation):> 1000

Ranking timeline:

Project Participation Performance(2012-01-01 - 2025-12-31 ):

Total Project Funding:

Total funding allocated to projects this organisation participated or coordinated

Funding per Partner:

Since 2014 individual funding per partner. If data is not available at CORDIS: total funding / No of participants.

Projects:

Leadership:

Total number of projects: 2
As coordinator: 0
As participant: 2
Sole participant: 0
Coordinator / Participant Ratio: 0*

*Ratio includes only projects with > 2 partners

Summary:

Total project funding [€]:Projects [No]:
Year:coordinator*participant*per partner  as coordinatoras participant
2013 0 3.872.919 754.961 1
2012 0 5.976.298 398.420 1
*n.b.: These numbers represent the total amount of funds allocated to projects this institution has participated in, not the funding allocated to this institution

Networking:

Partners:

Institution:Projects [No]:
AMSTERDAM BIOTHERAPEUTICS UNIT1
CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE1
GENOSAFE SAS1
HOTSWAP STOCKHOLM AB1
IGEA1
INSTITUT CATALA DE LA SALUT1
IQUR LIMITED1
LATVIJAS BIOMEDICINAS PETIJUMU UN STUDIJU CENTRS1
LUXEMBOURG INSTITUTE OF HEALTH1
MAGISTRAT DER STADT WIEN1
MAX DELBRUECK CENTRUM FUER MOLEKULARE MEDIZIN1
NOVARTIS PHARMA1
PAUL EHRLICH INSTITUT1
RHEINISCH WESTFAELISCHE TECHNISCHE HOCHSCHULE AACHEN1
UD GENOMED MEDICAL GENOMIC TECHNOLOGIES KUTATAS FEJLESZTESI ES SZOLGALTATO KFT1
UNIVERSIDAD DE NAVARRA1
UNIVERSITAETSKLINIKUM AACHEN1
UNIVERSITE DE GENEVE1
UNIVERSITY COLLEGE LONDON1
UNIVERSITY OF LEEDS1

Constancy:

Total number of partners: 20
Partner loyalty:
Frequent Partner: (> 2 projects): 0
Rare Partner: 20
Frequent / Rare Partner Ratio: 0

Project overview:

Start dateProjectacronymrolefundingpartners
2013-09-01Development of a universal influenza vaccine based on tandem core technology FLUTCOREparticipant3.872.9197
2012-11-01"Transposon-based, targeted ex vivo gene therapy to treat age-related macular degeneration (AMD)" TARGETAMDparticipant5.976.29815